RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Super-enhancers (SEs) are crucial for tumor-specific gene expression.
• Bromodomain-containing protein 4 (BRD4) inhibitors, like JQ1, disrupt SE-mediated gene regulation and show antitumor potential.
• Adult T-cell leukemia/lymphoma (ATL) is a distinct lymphoid malignancy with limited therapeutic options.

Purpose of the Study:

• To investigate the anti-ATL effects of JQ1.
• To explore the role of SEs in regulating gene expression in ATL.
• To identify novel therapeutic targets for ATL.

Main Methods:

• Treatment of ATL cell lines with JQ1.
• Assessment of apoptosis and cell proliferation.
• Analysis of RUNX1 and c-MYC expression levels.
• Evaluation of RUNX1 inhibitors AI-10-104 and Ro5-3335.

Main Results:

• JQ1 induced apoptosis and inhibited proliferation in ATL cells.
• JQ1 suppressed RUNX1 expression by disrupting SE-mediated regulation.
• RUNX1 inhibitors AI-10-104 and Ro5-3335 demonstrated IC50s of 1-10 µM or lower in ATL cells.
• AI-10-104 suppressed c-MYC expression, suggesting RUNX1 promotes c-MYC.

Conclusions:

• RUNX1 expression is regulated by SEs in ATL.
• RUNX1 is a potential therapeutic target for ATL, as it promotes c-MYC expression.
• JQ1 and RUNX1 inhibitors show promise as therapeutic agents for ATL.